Intradermal delivery is safe

Over the years, intradermal vaccination has been proved to be very safe with only minor adverse effects.

Studies have found that intradermal vaccination may be associated with a greater incidence of local reactogenicity that typically resolves quickly.

Adverse events primarily include local mild pain, swelling, and redness, but no systemic reactions*

For Adverse Events and Contraindications and Warnings and Precautions please see MicronJetTM Instruction for Use

*Marra F, Young F et al. meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses 2013; 7:584-603;


Extensive clinical experience

Wide range of clinical trials with a variety of vaccines and drugs

One of the largest intradermal vaccination databases in industry

Numerous Trials

In addition to global commercial sales, NanoPass’s MicronJetTM Technology has been used to administer over 30,000 injections to approximately 7,500 patients in over 60 completed and ongoing clinical trials

Validated Benefits

MicronJetTM has demonstrated a superior immune response with full dose and equivalence or a trend for superiority with lower doses (4-40%)

Consistent and shallow intradermal delivery

Due to its unique design the MicronJetTM– microneedle is one of the shallowest and most consistent forms of intradermal delivery

The easy-to-use MicronJetTM provides one of most shallow and consistent forms of intradermal delivery.

Its minute size (0.6mm) allows for shallow injection. Being barely visible to the naked eye makes it also significantly less painful than regular injections, as well as much less intimidating.

It requires a short learning curve, enabling practitioners to quickly learn how to use the device, and adopt it as a leading alternative.

  • Blebs of >6 mm were observed 99% of the time, evaluated in over 1,000 injections on more than 800 subjects
  • Significantly less painful and intimidating than a regular needle and syringe, with the potential for improved compliance
  • Pediatrics applicability, as demonstrated by large Phase III study on 6-week-old infants
  • Smallest hollow needle in the market allows for a practically painless injection

Practically pain free injection

As the smallest hollow needle in the market (just 0.6mm long), MicronJetTM microneedle allows for a practically painless intradermal injection  

When it comes to microneedles, its all about the size.

Keeping comfort in mind

Practically painless
Less intimidating than regular vaccination needle and syringe
Tested in wide age range (proven safety and immunogenicity in infants and elderly)

The device is commercially available with regulatory approvals in multiple territories and most major markets including the US, EU, South Korea, China, Brazil and more.